Marissa Hanify - Rubius Therapeutics Director Communications
| RUBYDelisted Stock | USD 0.08 0.02 17.00% |
Insider
Marissa Hanify is Director Communications of Rubius Therapeutics
| Phone | 617 679 9600 |
| Web | https://www.rubiustx.com |
Rubius Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4663) % which means that it has lost $0.4663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8531) %, meaning that it created substantial loss on money invested by shareholders. Rubius Therapeutics' management efficiency ratios could be used to measure how well Rubius Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Rubius Therapeutics currently holds 76.15 M in liabilities with Debt to Equity (D/E) ratio of 1.17, which is about average as compared to similar companies. Rubius Therapeutics has a current ratio of 4.54, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Rubius Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Rubius Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rubius Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rubius to invest in growth at high rates of return. When we think about Rubius Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 6 records | INSIDER Age | ||
| Caryn Parlavecchio | Scholar Rock Holding | 52 | |
| Tanya MS | Replimune Group | 53 | |
| Jean Franchi | Replimune Group | 58 | |
| Sushil Patel | Replimune Group | 53 | |
| MBA MBA | Scholar Rock Holding | 52 | |
| MBA MD | Scholar Rock Holding | 57 | |
Management Performance
| Return On Equity | -1.85 | |||
| Return On Asset | -0.47 |
Rubius Therapeutics Leadership Team
Elected by the shareholders, the Rubius Therapeutics' board of directors comprises two types of representatives: Rubius Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rubius. The board's role is to monitor Rubius Therapeutics' management team and ensure that shareholders' interests are well served. Rubius Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rubius Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marissa Hanify, Director Communications | ||
| Jose MBA, Principal Treasurer | ||
| Laurence MD, Chief Medicine | ||
| Dannielle Appelhans, CEO Pres |
Rubius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Rubius Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.85 | |||
| Return On Asset | -0.47 | |||
| Current Valuation | 22.18 M | |||
| Shares Outstanding | 90.4 M | |||
| Shares Owned By Insiders | 5.55 % | |||
| Shares Owned By Institutions | 72.61 % | |||
| Number Of Shares Shorted | 1.53 M | |||
| Price To Book | 0.42 X | |||
| EBITDA | (169.55 M) | |||
| Net Income | (179.67 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Rubius Pink Sheet
If you are still planning to invest in Rubius Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rubius Therapeutics' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |